Senescent cells in the development of cardiometabolic disease

Postmus, A. C., Sturmlechner, I., Jonker, J. W., van Deursen, J. M., van de Sluis, B. & Kruit, J. K., Jun-2019, In : Current Opinion in Lipidology. 30, 3, p. 177-185 9 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard



Purpose of review

Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases.

Recent findings

Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice.


The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.

Original languageEnglish
Pages (from-to)177-185
Number of pages9
JournalCurrent Opinion in Lipidology
Issue number3
Early online date2019
Publication statusPublished - Jun-2019


  • cardiometabolic disease, cellular senescence, insulin resistance, metabolic syndrome, senolytics, SMOOTH-MUSCLE-CELLS, CELLULAR SENESCENCE, ADIPOSE-TISSUE, ADIPOCYTE DIFFERENTIATION, AGE, FAT, ATHEROSCLEROSIS, P53, PROLIFERATION, ACCUMULATION

Download statistics

No data available

ID: 78815594